Home › Trial NCT07780968
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
- Trial IDNCT07780968
- StatusNot Yet Recruiting
- PhaseN/A
- Study typeObservational
- SponsorJazz Pharmaceuticals
- Enrollment300
- Start date2026-11-30
- ConditionsEsophageal Cancer · GastroEsophageal Cancer · Gastroesophageal-junction Cancer · HER2-positive Gastric Cancer · Stomach Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.